Effect of coadministration of single and multiple doses of rifampicin on the pharmacokinetics of fexofenadine enantiomers in healthy subjects

Drug Metabolism and Disposition

Volumn 41, Issue 1, 2013, Pages 206-213

  Kusuhara, Hiroyuki ^a   Miura, Masatomo ^b   Yasui Furukori, Norio ^c   Yoshida, Kenta ^a   Akamine, Yumiko ^d   Yokochi, Miyu ^a   Fukizawa, Shinya ^a   Ikejiri, Kazuaki ^a   Kanamitsu, Kayoko ^a   Uno, Tsukasa ^d   Sugiyama, Yuichi ^e  

^a UNIVERSITY OF TOKYO   (Japan)

^b AKITA UNIVERSITY HOSPITAL   (Japan)

^c HIROSAKI UNIVERSITY   (Japan)

^d UNIVERSITY OF THE RYUKYUS   (Japan)

^e RIKEN   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; FEXOFENADINE; HISTAMINE H1 RECEPTOR; MULTIDRUG AND TOXIC COMPOUND EXTRUSION 1; MULTIDRUG RESISTANCE PROTEIN; OATP1B3 PROTEIN; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 3; RIFAMPICIN; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG INHIBITION; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; ENANTIOMER; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; KIDNEY CLEARANCE; LIVER CELL; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE; STEREOCHEMISTRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AGED; FEMALE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; MALE; MIDDLE AGED; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; ORGANIC CATION TRANSPORT PROTEINS; REFERENCE VALUES; RIFAMPIN; TERFENADINE; YOUNG ADULT;

EID: 84871584584     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.048330     Document Type: Article

References (35)

1. Acocella G (1978) Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 3:108-127.
2. Akamine Y, Miura M, Yasui-Furukori N, Kojima M, and Uno T (2012) Carbamazepine differentially affects the pharmacokinetics of fexofenadine enantiomers. Br J Clin Pharmacol 73:478-481.
3. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, and Kim RB (1999) OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866-871. (Pubitemid 29347585)
4. Deguchi T, Kusuhara H, Takadate A, Endou H, Otagiri M, and Sugiyama Y (2004) Characterization of uremic toxin transport by organic anion transporters in the kidney. Kidney Int 65:162-174. (Pubitemid 38037501)
5. Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, and Kim RB (2002) Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 71:11-20. (Pubitemid 34124034)
6. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, and Hillgren KM, et al.; International Transporter Consortium (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236.
7. Gillard M and Chatelain P (2006) Changes in pH differently affect the binding properties of histamine H1 receptor antagonists. Eur J Pharmacol 530:205-214. (Pubitemid 43075490)
8. Hamman MA, Bruce MA, Haehner-Daniels BD, and Hall SD (2001) The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther 69:114-121. (Pubitemid 32225411)
9. Hirano M, Maeda K, Shitara Y, and Sugiyama Y (2004) Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 311:139-146. (Pubitemid 39287793)
10. Imanaga J, Kotegawa T, Imai H, Tsutsumi K, Yoshizato T, Ohyama T, Shirasaka Y, Tamai I, Tateishi T, and Ohashi K (2011) The effects of the SLCO2B1 c.1457C > T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans. Pharmacogenet Genomics 21:84-93.
11. Lappin G, Shishikura Y, Jochemsen R, Weaver RJ, Gesson C, Houston B, Oosterhuis B, Bjerrum OJ, Rowland M, and Garner C (2010) Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. Eur J Pharm Sci 40:125-131.
12. Lau YY, Huang Y, Frassetto L, and Benet LZ (2007) effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 81:194-204. (Pubitemid 46174816)
13. Maeda K, Ikeda Y, Fujita T, Yoshida K, Azuma Y, Haruyama Y, Yamane N, Kumagai Y, and Sugiyama Y (2011) Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study. Clin Pharmacol Ther 90:575-581.
14. Matsushima S, Maeda K, Hayashi H, Debori Y, Schinkel AH, Schuetz JD, Kusuhara H, and Sugiyama Y (2008a) Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol Pharmacol 73:1474-1483. (Pubitemid 351574837)
15. Matsushima S, Maeda K, Ishiguro N, Igarashi T, and Sugiyama Y (2008b) Investigation of the inhibitory effects of various drugs on the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 36:663-669. (Pubitemid 351468371)
16. Matsushima S, Maeda K, Inoue K, Ohta KY, Yuasa H, Kondo T, Nakayama H, Horita S, Kusuhara H, and Sugiyama Y (2009) The inhibition of human multidrug and toxin extrusion 1 is involved in the drug-drug interaction caused by cimetidine. Drug Metab Dispos 37:555-559.
17. Miura M, Uno T, Tateishi T, and Suzuki T (2007) Pharmacokinetics of fexofenadine enantiomers in healthy subjects. Chirality 19:223-227.
18. Motulsky HJ and Mahan LC (1984) The kinetics of competitive radioligand binding predicted by the law of mass action. Mol Pharmacol 25:1-9. (Pubitemid 14223246)
19. Niemi M, Kivistö KT, Hofmann U, Schwab M, Eichelbaum M, and Fromm MF (2005) Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br J Clin Pharmacol 59:602-604. (Pubitemid 40632253)
20. Nozawa T, Imai K, Nezu J, Tsuji A, and Tamai I (2004) Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther 308:438-445. (Pubitemid 38134202)
21. Ohuchi Y, Yanai K, Sakurai E, Fukui H, Yanagisawa T, and Watanabe T (1998) Histamine-induced calcium mobilization in single cultured cells expressing histamine H1 receptors: a relationship between its sensitivity and the density of H1 receptors. Int J Mol Med 1:355-360.
22. Robbins DK, Castles MA, Pack DJ, Bhargava VO, and Weir SJ (1998) Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16455) and its enantiomers in healthy male volunteers. Biopharm Drug Dispos 19:455-463. (Pubitemid 28474562)
23. Sahi J, Sinz MW, Campbell S, Mireles R, Zheng X, Rose KA, Raeissi S, Hashim MF, Ye Y, and de Morais SM, et al. (2006) Metabolism and transporter-mediated drug-drug interactions of the endothelin-A receptor antagonist CI-1034. Chem Biol Interact 159:156-168. (Pubitemid 43042623)
24. Sakugawa T, Miura M, Hokama N, Suzuki T, Tateishi T, and Uno T (2009) Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil. Br J Clin Pharmacol 67:535-540.
25. Shimizu M, Fuse K, Okudaira K, Nishigaki R, Maeda K, Kusuhara H, and Sugiyama Y (2005) Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 33:1477-1481. (Pubitemid 41323995)
26. Shimizu M, Uno T, Sugawara K, and Tateishi T (2006) Effects of single and multiple doses of itraconazole on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. Br J Clin Pharmacol 62:372-376. (Pubitemid 44215539)
27. Shitara Y, Itoh T, Sato H, Li AP, and Sugiyama Y (2003) Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 304:610-616. (Pubitemid 36152336)
28. Tachibana T, Kato M, Watanabe T, Mitsui T, and Sugiyama Y (2009) Method for predicting the risk of drug-drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein. Xenobiotica 39:430-443.
29. Tahara H, Kusuhara H, Fuse E, and Sugiyama Y (2005) P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion. Drug Metab Dispos 33:963-968. (Pubitemid 41002778)
30. Tahara H, Kusuhara H, Maeda K, Koepsell H, Fuse E, and Sugiyama Y (2006) Inhibition of oat3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid. Drug Metab Dispos 34:743-747.
31. Tateishi T, Miura M, Suzuki T, and Uno T (2008) The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers. Br J Clin Pharmacol 65:693-700.
32. Tian X, Zamek-Gliszczynski MJ, Li J, Bridges AS, Nezasa K, Patel NJ, Raub TJ, and Brouwer KL (2008) Multidrug resistance-associated protein 2 is primarily responsible for the biliary excretion of fexofenadine in mice. Drug Metab Dispos 36:61-64.
33. Yasui-Furukori N, Uno T, Sugawara K, and Tateishi T (2005) Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Clin Pharmacol Ther 77:17-23. (Pubitemid 40075385)
34. Yoshida K, Maeda K, and Sugiyama Y (2012) Transporter-mediated drug - drug interactions involving OATP substrates: predictions based on in vitro inhibition studies. Clin Pharmacol Ther 91:1053-1064.
35. Zheng HX, Huang Y, Frassetto LA, and Benet LZ (2009) Elucidating rifampin's inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite. Clin Pharmacol Ther 85:78-85.